Ilia I. Ouspenski

Array ( [id] => 18597284 [patent_doc_number] => 20230272079 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-08-31 [patent_title] => Monoclonal Antibodies to Programmed Death 1 (PD-1) [patent_app_type] => utility [patent_app_number] => 18/167012 [patent_app_country] => US [patent_app_date] => 2023-02-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 46102 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18167012 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18725845 [patent_doc_number] => 20230340070 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-10-26 [patent_title] => MULTI SUBUNIT PROTEIN MODULES, CELLS EXPRESSING SAME AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/085632 [patent_app_country] => US [patent_app_date] => 2022-12-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 31105 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 103 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18085632 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18724380 [patent_doc_number] => 20230338525 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-10-26 [patent_title] => VISTA MODULATORS FOR DIAGNOSIS AND TREATMENT OF CANCER [patent_app_type] => utility [patent_app_number] => 18/066581 [patent_app_country] => US [patent_app_date] => 2022-12-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 90937 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18066581 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18844531 [patent_doc_number] => 20230406935 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-12-21 [patent_title] => FC BINDING FRAGMENTS COMPRISING A PD-L1 ANTIGEN-BINDING SITE [patent_app_type] => utility [patent_app_number] => 18/063521 [patent_app_country] => US [patent_app_date] => 2022-12-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 40370 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18063521 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18612335 [patent_doc_number] => 20230279067 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-09-07 [patent_title] => FLT3 LIGAND FUSION PROTEINS AND METHODS OF USE [patent_app_type] => utility [patent_app_number] => 18/057604 [patent_app_country] => US [patent_app_date] => 2022-11-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18605 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18057604 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18612335 [patent_doc_number] => 20230279067 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-09-07 [patent_title] => FLT3 LIGAND FUSION PROTEINS AND METHODS OF USE [patent_app_type] => utility [patent_app_number] => 18/057604 [patent_app_country] => US [patent_app_date] => 2022-11-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18605 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18057604 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18612335 [patent_doc_number] => 20230279067 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-09-07 [patent_title] => FLT3 LIGAND FUSION PROTEINS AND METHODS OF USE [patent_app_type] => utility [patent_app_number] => 18/057604 [patent_app_country] => US [patent_app_date] => 2022-11-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18605 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18057604 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18451580 [patent_doc_number] => 20230192858 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-06-22 [patent_title] => ANTI-CTLA4 Antibodies, Antibody Fragments, Their Immunoconjugates and Uses Thereof [patent_app_type] => utility [patent_app_number] => 18/056681 [patent_app_country] => US [patent_app_date] => 2022-11-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 39390 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18056681 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18879143 [patent_doc_number] => 20240002512 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-01-04 [patent_title] => CANCER IMMUNOTHERAPY BY DISRUPTING PD-1/PD-L1 SIGNALING [patent_app_type] => utility [patent_app_number] => 18/052076 [patent_app_country] => US [patent_app_date] => 2022-11-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 39751 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 25 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18052076 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18939654 [patent_doc_number] => 20240034793 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-02-01 [patent_title] => CANCER IMMUNOTHERAPY BY DISRUPTING PD-1/PD-L1 SIGNALING [patent_app_type] => utility [patent_app_number] => 18/052099 [patent_app_country] => US [patent_app_date] => 2022-11-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 39720 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 25 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18052099 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18953668 [patent_doc_number] => 20240041995 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-02-08 [patent_title] => ANTI-ICOS AGONIST ANTIBODIES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/052110 [patent_app_country] => US [patent_app_date] => 2022-11-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 74683 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 41 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18052110 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18529994 [patent_doc_number] => 20230235062 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-07-27 [patent_title] => TARGETED BINDING AGENTS AGAINST B7-H1 [patent_app_type] => utility [patent_app_number] => 18/051773 [patent_app_country] => US [patent_app_date] => 2022-11-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 45885 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 89 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18051773 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19003648 [patent_doc_number] => 20240067719 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-02-29 [patent_title] => ANTI-HUMAN VISTA ANTIBODIES AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 18/045525 [patent_app_country] => US [patent_app_date] => 2022-10-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 55913 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18045525 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18339107 [patent_doc_number] => 20230131056 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-04-27 [patent_title] => sPD-1 VARIANT - FC FUSION PROTEINS [patent_app_type] => utility [patent_app_number] => 17/962983 [patent_app_country] => US [patent_app_date] => 2022-10-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 39369 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -23 [patent_words_short_claim] => 59 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17962983 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18612343 [patent_doc_number] => 20230279075 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-09-07 [patent_title] => T-CELL MODULATORY MULTIMERIC POLYPEPTIDES AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 17/959065 [patent_app_country] => US [patent_app_date] => 2022-10-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 75259 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17959065 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20372506 [patent_doc_number] => 12479930 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-11-25 [patent_title] => Proteins specific for BAFF and B7RP1 and uses thereof [patent_app_type] => utility [patent_app_number] => 17/936062 [patent_app_country] => US [patent_app_date] => 2022-09-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 15 [patent_no_of_words] => 10547 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 131 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17936062 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20372506 [patent_doc_number] => 12479930 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-11-25 [patent_title] => Proteins specific for BAFF and B7RP1 and uses thereof [patent_app_type] => utility [patent_app_number] => 17/936062 [patent_app_country] => US [patent_app_date] => 2022-09-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 15 [patent_no_of_words] => 10547 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 131 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17936062 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18808672 [patent_doc_number] => 20230383006 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-11-30 [patent_title] => ANTI-CD26 ANTIBODIES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/932822 [patent_app_country] => US [patent_app_date] => 2022-09-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 33582 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17932822 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18808672 [patent_doc_number] => 20230383006 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-11-30 [patent_title] => ANTI-CD26 ANTIBODIES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/932822 [patent_app_country] => US [patent_app_date] => 2022-09-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 33582 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17932822 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19571911 [patent_doc_number] => 20240376203 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-11-14 [patent_title] => ANTI-PD-1 IMMUNOGLOBULIN POLYPEPTIDES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/690247 [patent_app_country] => US [patent_app_date] => 2022-09-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28329 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18690247 [rel_patent_id] =>[rel_patent_doc_number] =>)